Soreness (DOMS) — Good Workout or Meaningless?

What Most People Think

"No soreness, no gains."

"If you're not sore, you didn't work hard enough." Soreness is treated as the body's receipt for a productive session. Its absence is taken as evidence of insufficient effort or an inadequate stimulus — a sign the muscles weren't challenged enough to grow.

This belief is deeply embedded in gym culture. Trainers use it as a quality marker. Athletes compare their soreness as a badge of effort. The logic seems intuitive: pain signals damage, damage triggers repair, repair equals growth.

The problem is that logic is wrong.

What the Evidence Actually Shows

Soreness and muscle growth run on separate tracks.

The Debate

Where the evidence conflicts

Honest Limitations

Where the lab meets the real world

The Practical Takeaway

What to actually do about this

• Chase progressive overload, not soreness. Add weight, reps, or sets to movements you've mastered. Minimal soreness from a well-run programme means your muscles have adapted — which is exactly the goal.
• Foam roll to manage soreness. It works (g=0.47 for pain reduction), costs nothing, and doesn't compromise growth. 5-10 minutes before training is enough.
• Cold baths are a poor trade if muscle growth is the goal. Wait at least 4 hours after lifting if you use them — that post-lifting window is when your body's growth signalling is most active. CWI during that window blunts it.
• Interpret the absence of soreness as a success signal. A trained lifter on a consistent, progressive programme who rarely gets sore is doing it right.
• Avoid high-dose NSAIDs if you're under 50 and training for muscle growth. The growth blunting at standard therapeutic doses (~50% in quad volume over 8 weeks) isn't worth the pain relief. If you're 65+, the calculus reverses.

The Nuance

What the simple answer misses

• Novices will experience soreness because any novel stimulus causes eccentric muscle damage. For a beginner, soreness is an expected side effect of starting training — not a target. The goal is to move through that phase, not extend it indefinitely.
• Heavy compound lifts with high eccentric components (Romanian deadlifts, squats, rows) will incidentally produce mild-to-moderate soreness in most people. The point is not to avoid this — it's not to optimise for it.
• Occasionally feeling sore from a new exercise is diagnostic, not directional. It means that muscle group is unaccustomed to that angle or load — not that it grew more.
• Adults 65+ are a genuine exception. Chronic systemic inflammation in older adults ("inflammaging") suppresses protein synthesis at rest. Anti-inflammatory strategies — including NSAIDs — can actually enhance their muscle growth by 35% by lowering the pathological baseline. This is the opposite finding from young adults.
• The NSAID exception cuts both ways by age: high-dose ibuprofen is a growth-blunter for young adults and a potential growth-enhancer for older adults. Age matters more than the drug category here.

Conviction

Convergence across molecular biology (mTORC1 assays), tissue imaging (ultrasound/MRI cross-sectional area), isotopic tracer data, and neurophysiology (Repeated Bout Effect literature) is unusually robust for exercise science. The mechanistic independence of soreness and hypertrophy has been validated at multiple levels of biological organisation.

Sources

Key references

• Damas et al., 2016 — Journal of Physiology, N=10, 10-week RT with D2O isotopic tracer. Early muscle protein synthesis correlated with repair, not growth; late synthesis correlated with actual hypertrophy as soreness attenuated (r≈0.9, p<0.04). First direct evidence separating repair from growth at the molecular level.
• Flann et al., 2011 — Journal of Experimental Biology, N=14, eccentric cycling RCT. Pre-trained (zero DOMS) vs naive (severe DOMS) — identical hypertrophy outcomes (6.1% vs 7.0%, not significant). The definitive head-to-head trial.
• Fyfe et al., 2019 — Journal of Applied Physiology, N=16, 7-week RT + cold water immersion. CWI attenuated Type II muscle fibre growth (ES: -1.37) and blunted mTORC1 phosphorylation. Effect disappears when CWI is delayed ≥4h post-training.
• Lilja et al., 2018 — Acta Physiologica, N=31, 8-week RT + Ibuprofen 1200mg/day. Ibuprofen group gained ~3.7% quad volume vs ~7.5% in low-dose control (p=0.029). 50% blunting at standard therapeutic dose.
• Wiewelhove et al., 2019 — Frontiers in Physiology, meta-analysis of 21 studies. Foam rolling reduced soreness (g=0.47), trivial effect on performance (g=0.06–0.21). Mechanism: neurological, not mechanical tissue remodelling.
• Konrad et al., 2024 — Frontiers in Physiology, N=30. DOMS produces 40% eccentric strength loss and 31% increased secondary injury risk during the 24-72h soreness window.